- Home
- LGTY vs KROS Comparison
LGTY vs KROS Comparison
Compare LGTY & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGTY
- KROS
- Stock Information
- Founded
- LGTY 1970
- KROS 2015
- Country
- LGTY United States
- KROS United States
- Employees
- LGTY N/A
- KROS N/A
- Industry
- LGTY
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- LGTY
- KROS Health Care
- Exchange
- LGTY NYSE
- KROS Nasdaq
- Market Cap
- LGTY 501.6M
- KROS 465.2M
- IPO Year
- LGTY N/A
- KROS 2020
- Fundamental
- Price
- LGTY $14.26
- KROS $10.16
- Analyst Decision
- LGTY Hold
- KROS Buy
- Analyst Count
- LGTY 1
- KROS 11
- Target Price
- LGTY N/A
- KROS $30.00
- AVG Volume (30 Days)
- LGTY 629.4K
- KROS 696.9K
- Earning Date
- LGTY 02-20-2025
- KROS 05-07-2025
- Dividend Yield
- LGTY 3.09%
- KROS N/A
- EPS Growth
- LGTY N/A
- KROS N/A
- EPS
- LGTY N/A
- KROS N/A
- Revenue
- LGTY $101,873,000.00
- KROS $3,550,000.00
- Revenue This Year
- LGTY $2.14
- KROS $16.65
- Revenue Next Year
- LGTY $3.93
- KROS $107.46
- P/E Ratio
- LGTY N/A
- KROS N/A
- Revenue Growth
- LGTY N/A
- KROS 2250.99
- 52 Week Low
- LGTY $8.41
- KROS $9.71
- 52 Week High
- LGTY $14.29
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- LGTY N/A
- KROS 30.00
- Support Level
- LGTY N/A
- KROS $11.18
- Resistance Level
- LGTY N/A
- KROS $11.63
- Average True Range (ATR)
- LGTY 0.00
- KROS 0.40
- MACD
- LGTY 0.00
- KROS -0.03
- Stochastic Oscillator
- LGTY 0.00
- KROS 12.56
About LGTY LOGILITY SUPPLY CHAIN SOLUTIONS INC
Logility Supply Chain Solutions Inc develops enterprise management and supply chain-related software and services. Its Services include Scenario Planning Products, Demand Planning InventoryAI+, Supply, Deployment, Supply Chain Data Management, and Supply Chain Design. The group provides services to various industries such as Food and Beverage Consumer Packaged Goods, Process Manufacturing, Industrial Manufacturing, Chemicals, and others.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.